{"ticker": {"uuid": "fea876ac-6f7d-46b8-a241-170093a0833c", "symbol": "VTRS", "name": "Viatris Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Viatris Inc. stock rises Wednesday, outperforms market", "summary": "Viatris Inc. (VTRS) stock increased by 2.27% on Wednesday, closing at $16.68. The rise came during an overall positive trading session, with the S&P 500 Index gaining 0.38% and the Dow Jones Industrial Average gaining 0.29%. The stock is currently 4.85% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/viatris-inc-stock-rises-wednesday-outperforms-market-bd585bab-550b09e5348c?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-15T17:07:00", "published_display": "15 Jul 2026 17:07", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Report: Viatris Inc.", "summary": "", "url": "https://finance.yahoo.com/m/efa67aab-cc2b-3109-8173-4d7e0d59b41a/analyst-report%3A-viatris-inc..html", "source_name": "Morningstar Research", "published_at": "2026-07-14T20:05:13+00:00", "published_display": "14 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Looks to New Launches and Cost Savings for Long-Term Growth", "summary": "Viatris, a major generic drug manufacturer, is focusing on new product launches and cost-saving initiatives to drive long-term growth. The company expects to counter the erosion of sales in generic drugs in developed markets by concentrating on complex generics. This strategy aim", "url": "https://www.morningstar.com/company-reports/1487944-viatris-looks-to-new-launches-and-cost-savings-for-long-term-growth", "source_name": "Morningstar", "published_at": "2026-07-14T20:09:32", "published_display": "14 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XS332542958 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the Viatris Inc. 4.25% bond, identified as XS332542958, which matures on June 17, 2033. It highlights key facts about the bond including its coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also inc", "url": "https://www.tradingview.com/symbols/FWB-XS332542958/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T02:39:46", "published_display": "14 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Viatris, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Viatris, Inc. stocks, providing key financial data for each. The data includes market value, weight of Viatris in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, chang", "url": "https://www.tradingview.com/symbols/LS-A2QAME/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T01:39:43", "published_display": "14 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mylan to sell up to $363 million stake in India\u2019s Biocon, term sheet shows", "summary": "Mylan Inc., part of Viatris, plans to sell up to 92 million shares, or 5.64%, in Indian drugmaker Biocon Ltd, valued at approximately $363 million. The sale represents a secondary offering with a floor price of 378.50 rupees per share, a 7.9% discount to Biocon's last closing pri", "url": "https://wtvbam.com/2026/07/13/mylan-to-sell-up-to-363-million-stake-in-indias-biocon-term-sheet-shows/", "source_name": "WTVB", "published_at": "2026-07-13T21:09:18", "published_display": "13 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE5282055 Bond Risk Profile", "summary": "This page provides a risk profile for the Viatris Inc. (PFE5282055) 4.0% bond maturing on June 22, 2050. It details key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. The pl", "url": "https://www.tradingview.com/symbols/FINRA-PFE5282055/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-13T19:39:19", "published_display": "13 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mylan to sell up to $363 million stake in India's Biocon, term sheet shows", "summary": "Mylan Inc., a part of Viatris, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, amounting to approximately $363 million. This secondary sale represents up to 5.64% of Biocon's outstanding shares, with Biocon not receiving any proceeds from the transaction. Th", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/mylan-sell-up-363-million-stake-indias-biocon-term-sheet-shows-2026-07-13/", "source_name": "Reuters", "published_at": "2026-07-13T14:39:10", "published_display": "13 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon", "summary": "Mylan, a unit of Viatris, intends to sell up to 92 million shares, representing 5.64% of Biocon's outstanding shares, in an offering potentially worth $363 million (Rs 34.81 billion). This secondary sale will not provide any proceeds to Biocon, and the shares are being offered at", "url": "https://www.business-standard.com/companies/news/viatris-unit-mylan-plans-to-sell-stake-worth-up-to-363-million-in-biocon-126071301168_1.html", "source_name": "Business Standard", "published_at": "2026-07-13T14:34:19", "published_display": "13 Jul 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(VTRS) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Viatris Inc. (NASDAQ: VTRS) through an institutional tactical lens, identifying strong sentiment across all time horizons. AI models have generated distinct trading strategies, including long, breakout, and short setups, with specific entry, target, and stop", "url": "https://news.stocktradersdaily.com/news_release/141/VTRS_as_a_Liquidity_Pulse_for_Institutional_Tactics_071026071402_1783725242.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T19:38:55", "published_display": "10 Jul 2026 19:38", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14", "summary": "BofA Securities has reiterated its Sell rating on Viatris (VTRS.US) and increased its price target to $14. This revision suggests a potential downside from the stock's last closing price of $19.53.", "url": "https://www.moomoo.com/news/post/72780960/bofa-securities-maintains-viatris-vtrsus-with-sell-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-10T12:38:50", "published_display": "10 Jul 2026 12:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS)", "summary": "Viatris (VTRS) recently announced positive Phase 3 results for VR-205 (Nefecon) in Japanese adults with IgA nephropathy and refinanced a JPY 40 billion loan. These developments are seen as critical steps in the company's strategy to shift from generics to higher-value specialty t", "url": "https://www.sahmcapital.com/news/content/positive-iga-nephropathy-data-and-yen-loan-recast-could-be-a-game-changer-for-viatris-vtrs-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T00:09:12", "published_display": "10 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Inc. stock falls Thursday, underperforms market", "summary": "Viatris Inc. (VTRS) stock declined by 1.92% on Thursday, closing at $16.34, performing worse than the broader market. This marked the second consecutive day of losses for the stock, despite both the S&P 500 Index and the Dow Jones Industrial Average closing higher.", "url": "https://www.marketwatch.com/data-news/viatris-inc-stock-falls-thursday-underperforms-market-adf526c1-366a73e5eb65", "source_name": "MarketWatch", "published_at": "2026-07-09T21:09:19", "published_display": "09 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Viatris (VTRS) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOSU5aNkU5SkpEMDZ1Uk8tWXVzeUJRcmd0aHR0RDhlOE9zbHh4b1Y5dzJjZWd2M3BhaXFDWHZXZlMyVTFtZ241MUR6akk1eEtydHhCdWJPdUs0Nmp6NmZyVUV3QktUNEtrUnRFY2V0cG9fVDhqZEVlWHV3SHhTWllpeUZLc21rS1hTV2JxcXJXVHFlU0cxRjViT0hNdk9ldw?oc=5", "source_name": "Market source", "published_at": "2026-07-09T13:40:05+00:00", "published_display": "09 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Inc. stock falls Wednesday, underperforms market", "summary": "Viatris Inc. (VTRS) stock fell 1.77% on Wednesday, closing at $16.66. This decline occurred during a generally down day for the market, with the S&P 500 Index and Dow Jones Industrial Average also recording losses. The stock\u2019s drop ended a four-day winning streak.", "url": "https://www.marketwatch.com/data-news/viatris-inc-stock-falls-wednesday-underperforms-market-daf21657-e09e77f24f4d?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-08T17:04:00", "published_display": "08 Jul 2026 17:04", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now", "summary": "This article highlights three healthcare stocks\u2014Kenvue (KVUE), Pfizer (PFE), and Viatris (VTRS)\u2014all trading under $30, presenting value opportunities for investors. Kenvue is amid a strategic acquisition by Kimberly-Clark, offering a defined takeout floor. Pfizer boasts a 7% divi", "url": "https://247wallst.com/investing/2026/07/07/3-dirt-cheap-healthcare-shares-under-30-to-buy-right-now/", "source_name": "24/7 Wall St.", "published_at": "2026-07-07T17:38:07", "published_display": "07 Jul 2026 17:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Viatris\u2019 Japan IgA Nephropathy Win and New Loan Shape VTRS Investors\u2019 Next Move?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/viatris-japan-iga-nephropathy-win-090906120.html", "source_name": "Simply Wall St.", "published_at": "2026-07-06T09:09:06+00:00", "published_display": "06 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results", "summary": "Viatris Inc. (VTRS) recently secured a \u00a540 billion senior unsecured term loan to support business operations and refinance an existing loan, with interest rates tied to the TIBO rate plus 1.10% and credit ratings. This financial move follows positive Phase 3 results for its drug ", "url": "https://www.insidermonkey.com/blog/viatris-vtrs-secures-loan-amid-positive-phase-3-results-1795820/", "source_name": "Insider Monkey", "published_at": "2026-07-05T22:57:51", "published_display": "05 Jul 2026 22:57", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now", "summary": "Viatris Inc. (NASDAQ: VTRS) is highlighted as one of the most undervalued NASDAQ stocks, following positive top-line results from its Phase 3 clinical trial for VR-205 in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The treatment demonstrated a significant re", "url": "https://www.insidermonkey.com/blog/viatris-vtrs-most-undervalued-nasdaq-stocks-to-buy-right-now-1795978/", "source_name": "Insider Monkey", "published_at": "2026-07-05T13:08:57", "published_display": "05 Jul 2026 13:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTRS Stock Price and Chart \u2014 NASDAQ:VTRS", "summary": "This page provides a detailed overview of Viatris Inc. (VTRS) stock, including its current price, historical performance, key financial metrics, upcoming earnings reports, and analyst ratings. It also offers insights into its sector, industry, and corporate information, alongside", "url": "https://www.tradingview.com/symbols/NASDAQ-VTRS/", "source_name": "TradingView", "published_at": "2026-07-05T07:39:12", "published_display": "05 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Refinances $247.7 Million Term Loan", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/viatris-refinances-247-7-million-105651551.html", "source_name": "MT Newswires", "published_at": "2026-07-02T10:56:51+00:00", "published_display": "02 Jul 2026 10:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWldfWFV6NXFPUmxoWWRPZDU2TnRBX18tdHdXN1AwQk95Mmo1al9LTzA0TnVjd3U3ODBmcmdmdngxNTA2S05ma3lKN2hvN2RqOW9DclAyUWlUWmcyakxKVjVyNl9Jc0FxZk1wcEc5SHRmS3VtQVN2MjJTcjluMHdJQlk5b1dRQXRxTFBUbFZhZTVibjhqbmRCZllGQTctWFk?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T11:53:51+00:00", "published_display": "01 Jul 2026 11:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris sets Aug. 6 call for second-quarter 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQV0FnblV2NlNmelNfcVJnTHIzZzRnUWFUSVhGT2doMlFhRHhkZWFab3huN0FwdWtjZ0N3VGM1RXVuSF85VEM3cWpodGZBSFhwUVZIb1dFR09CLTVkRzJBU3FyS2xYWEtlbWloWklGdFZJeko2c3VnbVRmZWlXTXZKRm45bUFtV1FXa01SMTNkU0FNUnNqTS1OWHAxMldKSmE3NGdZcTVxeFNGTmNCbjkyOXdnd2c2Tmg1cFJTcXZXSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQc3RxX0MwQ2Y0bU9VaHJjYVJJNkxpMm15M09EOHNaeXl2QWZPNTZmSDgxamJHdFE2cnoxLUU3OUNxOGcxSVQ1LUtfa0xUR2V1dkdPSEttT3ZIc2NpdkQ0VnNjM0VWYk9fenJlX1ljUjVpRklNQjQxdS15M1hjX3FVSEZsSWhYcHJaTDcwZVNuZjRpWU9OanhZZDg0andOR1ljQU1HVnowMEY?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris kidney drug VR-205 cut protein in urine 33.75% in Japan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMzBMQm1PTjZHQjhGMHhydGc3V0w4Y1M2M3B3UDB0NDNfc3pram0zZVRkdFFMTUx6aG1MYVNNNV9KMEpXXzdWWXdHMVJjSUNxU0lkN2UtUGhtUkJiNEtRaWFQNmtOaDI2b1M3VEZfZ0t5NjItYjY0VWxxTVN3THh1SlpUcl9VT2RiMUgyRTVJbGc2MG05M25xM3lNTFV3d2l2ZVBpbW5FbHhrc3RhaFhNWjk3MHRrZFNLTlhXNXk0NUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPNlhGRkkyWWJ6dFo2akxUVVJuNWZVMTIyZTlyODdxYmxfRkZOWGdJc0pyMDVNRi02cy1jcERiSm9lNzgtSE92NG1ITEsyS2JKYnlISFhUQm5SbG1sX212UUI5MllfbEE2d0VHVzBRSDBpcVdzWVRsUFdaT2dtRGNJUEx1WDBodTdtS0ktamlCbGxPUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Investors Undervaluing Viatris (VTRS) Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdm1EY1ItZDB2NHNVVVloYk1DSGNrdFNkT3pDX0xtRlIzWFRDUjVldDhhcGhIZndoT2dQbXh4MHRaNzE1RkdIODJkQXpsVVI2ZlZVVVN6NDV2bEYwdHFBSXgzQkQxQ1ItNU1mZTJjd0RndVZlc00zZXZtN1djNDE0Z2F4WDBLUXNzeXhpUHR2QmU2b2dwRlNZZzZYUW5qNWF5UjlCU2MxWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOLUdCcnhvb1ItdGFnMGViU0xJS2RTNHhMbWZXY0pQZzRzWEplTGhKSkZ2QVV1Nm5KdldjWi1ON3hSMVBSQTBST0ZIaWNlc0hTM2NPSUtBcW9UdWdZUkEtLWp3RXJ6dUFvT1VxX3ZIT1Y2clhHUlFiVlFqSzcwblQ2N2Z4Q25NWGowQ251TnU0a1VpcmNna0laaE9CYnUxdEtiTkdNTHVsRkRDVWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (NASDAQ: VTRS) issues \u20ac650M 4.25% notes to help refinance 2026 debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQeFV0OW5xcFlxQWdKWmFlck5JbG5TMXdoSFFyajA0bHhEX082VFQ1c0g3VG5ESGdKWEgwUkJMck1vby1OeDhUaWJraVhQTkRJUEZtYkdveDF2UWd5N21HVk16Qm9jSC1YVS1CMHdGVkZ6MkUzY1QwUDRILS1yMmNBY2w2dUZ2SWFaX0tLYlNtaVB0NGJEdzd3bEJzR1owOFlSd3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSF8tX0FQYm9VUzdLazA1bjhsMWNraV8wLVJGNnNxYk1Xemc4WUxiZGF6LXlRMjNJX0RpaHFreC1IalNYODhpN01PdXhib3NTeU9GY1l3Um5OLXVaZ18taFFFV1RoaFptOVZ5Vm52LTdCSUtIY2ljX2FNanR5TmNRR3BrUTRuOHJIUG5lUlpyN3E1YW5taV94Q2VUZGE3Y3ZrQjVn?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQOHlLMGRzNDRfZlpiS0pBcTRsek1zOVVuNVN1WHo5NmNqU29OcS16YXZpZXpZSTZ6cWhWYm5EM1dOUTVqcFRZaXpiQVdwS2lCZmNTVXRmNlBkMlBVeW4tekxzZlNKLW91NDFMaC1XN2hVWEdDRG1VQ1FmcjEzRjl6SkF6anhxdVdkdGwxYUk5bmdCZlhzaXc?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUmJ1U0VSY1hqRUt4MnpWUkpMY29tbnRYMUxZdmkxVTM0M1JOd1FaWENYaVJWbzBWU3J5N0x4UV9YM0dDeTdRWW1KVXppNTRUUkVzdVY4RlVqa1E5OEg4cVVoY2p3Vms5bWNQQ3U3NzV4Szdmb0FqX21HanVOSTU2OTBYOGswcWkzc0NGbW1mUVBONHlYNlQ1c1RPQVBOQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New non-opioid pain drug from Viatris faces FDA decision on Dec. 27, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOVnZnbDh4UTZPMWpXZ2lGU3Z0OGt5SEhJX0Ytcl9oczg2Y2EwVDZodmprV2t4NUo1Rlk5UmhyYmFaS3E0bzhJQmktYTBKNlppTmgwSmYwWXZ4YXBacXhMVGNpUDRuY2ZFY3hFR2tuUGFSUjR0WkVqNFpwVThSb2JJbnh6OUF4cTF5MElOT04wQ0pUZGRCWC1IVGhnOXliekl4YThXV2FFaFY3ejd5ZjhrOVg1RTVDdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Kicking Off 2026 Solidly, Viatris Looks to New Launches and Cost Savings for Long-term Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQdTByUUg1VmM4YjlDUWZqMzVLa2xUZjFyMzU5clVnVndMdEljSmxjSVAyV1hrVThlVm9XLXFDLUx3Umk1dXF2UUNaMmhaTE02UVhuR3dBVlFXbVEtb2dPMFFNaTl0SmdWMGEzazVOOEdSejVIcWRUNWhuenNZR0RRbjFtQ2FqdTBfTkREQU5QZjBUMXRrbTZydWFXa3RCbEtxTlNXc2hveTgtenAxOUZFcldDOWRzTUM0VWsxODFqbmRpcmFxSl9VRFcwaHd1TWJ3Ni1wRklKMnFONWlKSzNxQmtGTkE?oc=5", "source_name": "Morningstar", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris\u2019s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxON3RGZGo0dFVuQXpkNWZPUFAtZDJSdEowTzRtcDJjbE4yQ0xkXzhEZHNKd3hZaHY2eW82dnhPc0hEckhBZVo0amtSd3NtZmtvb2RLY3pROTJ6SS1EQkxVM2Fycy1RR0NQNWtaUDMyZDQzWWFxOUdoRkM3YXlQejYzRmpFME9uSHZ3OV9EWVppV3BvUHpCSDRiS0JB?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPdzFiOHNsX2xncWlWdnl2c1dVbWppUXZILVNuby1UMTlfenJFeTd0OEwyWEpoWmg2TFFoMDZLOGwzY3RWa2tCUmN3N0pPNmswMG1udF9NVnlOREZGVVZzb2dfbmZpY05iZWIzWDRxd2NQb3hoRGJ0M2F1V25HaGozWV9xb20zUThGTEthRkZJWTE3MXBM?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Reports First-Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOQzN4MmVad1pXU2RZR3RDaDE5YW94SkVJMzZadF9qRDltOW1EX0Y1aDhSYnp6ZGxiNVNLamo1RFBxUk5SUmdTa0ZpUEE3Vno4aGo0TWlEdEs3blAyNllMRF80aEwxRkFQcXJZMzR2Zkx5N2gyWE1GVWVkd1dROEZUUEIzWjBJNzhVMDdyTmdSS2hwN3VFRThXTzlvajAzSjViTlFBMFIwdHlRSEJf?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Viatris (VTRS) Valuation After Its Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOb0VXellib3lsM0JjNnBjTlQ5M3g3WkJMcGl6UE5VSU5VRXFkeWd6SW5OcWJtYUNXZFlpWFFYZEtYRmgtODZqMURaVEhadnh1Y2taRU1pa0liNkZVc0xSa3laVngzUXN5VXNjNEJDTGx1WWpMSUU0TEVxUzREaDVGaW41SVdFc0k5ZVQ2ZXZlOU53aGxsc3ctR0FkdzltQ1dOb2RqNFM4MA?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Bullish on Viatris Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQd0RPWEluUFZjTm5OZHJFUHZ2cUxNd2V0aENPNzBZNjdrb19ZZ1J5Y0QweklrY09mV1hGSWdyQXVwYkw1Y25kQW5ua3dIZkNTX0xSbEdJSWVkbmJCWk1hWjhneWwzLXZ2dW9TbTNrc2hwNmNuN3UzMFVmY1RmcGZwSS1rbWdKOEFWR0ctTUVCVjdkV3ZZRVNmY1BJTUI2ODFQT1Bj?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Davis Selected Advisers (NASDAQ: VTRS) reports 78.21M shares, 6.8% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOcHk0bjJqRWpBMGxtaktNZ0Nfa1hQMnNzQ0lOU0hLMm9iRXNibkpTRmhuVVlPbUdCcWdsNTJkb3JiQkpMMWhjcldOTzVWbGxjSGVRU2c0Y2tNS2tZVXlPbjlnRFBEMkxZTjVmMTVyeXZuYTA3bXA5RUhscGtMdmcya2Y1dXZQUkRaUlNzOXJBakp1SjFzM3lXOC1nR1drRllVbmJxNDZ3bk9qSFdqeTNpMlVkVlBMM0xabW5oXzYxSC1Xd2Rm?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Viatris (VTRS) After Its Strong One Year Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPZnBKVlhlM2VpbVdJRzV2dmxTQ3Vna0pRMGdOWXduRk1BdnpoYkVvZF9hTUVFdmc2Ym55N2k3dXpTcUhGNVNybXZGa3A3b2NIdHdyMERlSEp2TmhkZlJ0S2FrRmtMUVNhcXZENk9EM0g4ZmhnUnpBTmJpWmd4cWRIampUREdmc3lkUjBiOG81UVZTUGQ5azZmVl9TYTJLZw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Contraceptive Patch Data Puts Women\u2019s Health Growth Story In Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQQjNCQnZwTkZKR1lTNEdhRlNQVTNTaVJIR2xfVTJqYmZfYnNQaFcwUHVFNTFMR2ZaVS1sSV9idmxWTll0UGd3U1ZVNzZha1VXZlNrWDVzSFJYV1lsU01ZcWVoWmRYdFFqbUxBM0N4QXlIWThzZXo4b0h1OVhuNXBmY3h3VUhaTnZWS3Q0emE0VVVxcC1pOEtNeUlB?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNbmZvVFBTcU5wOTVSbTNqQzZLT0d3V0VGTUNwMlRRY1plODF3UV93Y2I1b2taRm1xSEVPY2VxVWJoSS1odHVJNDRhUzVkN2Itb3ZYWUI3TUotVXBTWlRRUkZCOEgtZ0tzb0htdzVCanZwaENMMlRoSm1yZVYtVXVhOGlfeXNkUWJRTDZRY2hRQWpDRktzOVVBRmw4dkhEdDJOeXlpU3FYd2c5cDFzMy15MnZKWEhpVm9sbEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris, Teva kick off separate recalls over dissolution, raw material issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSEY1Y0VZNWh6OU0wU2Jmc2tqRXdQSUlUeWlnZFBMcldhTjVabUtrbFlTZmlqand4alg1NjVZZmxnSzgtXy1hY2xDeXlkMjQ3SWtmZmUtOXdCbFR4N0p0Vm9nTGRBQlFTOVpXZU5EdXJ6b25HcVZVQ3BDY0U0RU15TGRJcV9WWE9feHpjc3VRNFNlOFdRQngtNGZSOWVibndtVENUeEl4ZVpRWkhjLVFjWVFlOWZLZUVfMFFnSGFndFE1WkU?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPcHdSNEhpWnZwX3ptTVFTTmF1YWZSSDlkLS1iSkRIU3EyZFpfNzhGNjJ4VDVWV01KbW05UW9CbTIta3FWYzhqV0c3S2p5Qlpzak9icy1jZlBsNkM2d3lsTG93R0t1bzAzZWRodFdqd1NjblNBUnlMc1VFN183Rks4b09mMDEtNHFXdzlZVDlCV1dNckd2X2NjX2JaT0tUY202emZXRG5ubEtiR0dkaVR0aVY3NGF0WE1ORzloOVI1cEpjdXN6UHhsY1QtUE9xcUJLMjFhVkIwTQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Are Analysts Saying About Viatris Inc (VTRS) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNbUx4cTRRd2xNZVd2S0lTci1KUXNNLUUtTzY0WkNtWWZfZkt4cnhpUlhJUTRvLUJaeEhjVjBEWHJJWGZIZDJYb3JBRE5Dendfb29HaHhkZVQ5V1FwakJPQTZSekVoeC1zOWxweTVFZjlqWGpCY2VOdkNIU1ZySFZlWVBjcXI?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMkxMWTBBTHZmUFktRzN0LVdQbDBzNWFGV0ZkSGZBZHp0MGViT1g1S3V0d0EzSVM2ejh0VjdiQ05oUFA4MGx0MDg0VnJJTU1rWXVVeVVXQ2wzZVNsZEdsVFR6VUd3WjVjNUJBRTFFMjJvOWY1a0V3S2xIamJGLTNHSExKV1pOX081SmlnZGRXX2QzWU5XOGZBS0tYbHgzTjBwQ1AxOUY0MVZBR3pRVHBjdGNFYmZkRHdWalEwcFBMc2E?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where is Viatris Inc. (VTRS) Headed According to the Street?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNTTdOeW1TZEhTU3E3RHE1UWpwUUVpdUVMSU1YRG5DYkF3SkN0Zm9RR2R5MG5xOEV1Tm1tMW1pVV9rZU1hd0xpbkg1Z3ZQeTlNMU1DRE5RalFzY0U0RXZ2LXMySWluYU9SRXhrSE01dkVVVjdRU0V6NUtxMDc2MTFxZA?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viatris (VTRS) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1jeVp4Z1hSeVFhdU8xYlRUeEVabWtmV2dGbVVsU1hySzlOZVdiaXVrZTZpXzdFcm1odGhjYWhtTzhuZ0hHTWNvNm1SbXdNaFFMaEs4YUI4ME44UkxueklfU3c0dnQ3SUZ0dk9iRE96M3laNnBjNXZFMzVmdXNQYW8?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNQnZQR3NNUTBmSWs4QllVaTBiYS1POGM4RWpHc2tZV3VLUFNiWG1hT2VncE85cy12MmpMcWQ1cG84bjBJN3Vicjg3aHVZQy1XcHloQ3ZoUUNVUmlPbUlsU2pVZURXZ1VMcTVGZlk0TkJiNm9fWV9WUzhnVGpNMklrbFc5TzZsZlgzNXlZNmhkaW5WVWxvQmw2bDBka0tUUjRTTVBCUHVmenhhQ3BjSFB5c0E2WlJLcGJKUnc?oc=5", "source_name": "Viatris Newsroom", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Viatris Inc. stock rises Wednesday, outperforms market", "summary": "Viatris Inc. (VTRS) stock increased by 2.27% on Wednesday, closing at $16.68. The rise came during an overall positive trading session, with the S&P 500 Index gaining 0.38% and the Dow Jones Industrial Average gaining 0.29%. The stock is currently 4.85% below its 52-week high.", "url": "https://www.marketwatch.com/data-news/viatris-inc-stock-rises-wednesday-outperforms-market-bd585bab-550b09e5348c?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-15T17:07:00", "published_display": "15 Jul 2026 17:07", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Report: Viatris Inc.", "summary": "", "url": "https://finance.yahoo.com/m/efa67aab-cc2b-3109-8173-4d7e0d59b41a/analyst-report%3A-viatris-inc..html", "source_name": "Morningstar Research", "published_at": "2026-07-14T20:05:13+00:00", "published_display": "14 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Looks to New Launches and Cost Savings for Long-Term Growth", "summary": "Viatris, a major generic drug manufacturer, is focusing on new product launches and cost-saving initiatives to drive long-term growth. The company expects to counter the erosion of sales in generic drugs in developed markets by concentrating on complex generics. This strategy aim", "url": "https://www.morningstar.com/company-reports/1487944-viatris-looks-to-new-launches-and-cost-savings-for-long-term-growth", "source_name": "Morningstar", "published_at": "2026-07-14T20:09:32", "published_display": "14 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XS332542958 Bond Profile \u2014 Key Metrics", "summary": "This article provides a detailed profile of the Viatris Inc. 4.25% bond, identified as XS332542958, which matures on June 17, 2033. It highlights key facts about the bond including its coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also inc", "url": "https://www.tradingview.com/symbols/FWB-XS332542958/profile-overview/", "source_name": "TradingView", "published_at": "2026-07-14T02:39:46", "published_display": "14 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Viatris, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold Viatris, Inc. stocks, providing key financial data for each. The data includes market value, weight of Viatris in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, chang", "url": "https://www.tradingview.com/symbols/LS-A2QAME/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T01:39:43", "published_display": "14 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mylan to sell up to $363 million stake in India\u2019s Biocon, term sheet shows", "summary": "Mylan Inc., part of Viatris, plans to sell up to 92 million shares, or 5.64%, in Indian drugmaker Biocon Ltd, valued at approximately $363 million. The sale represents a secondary offering with a floor price of 378.50 rupees per share, a 7.9% discount to Biocon's last closing pri", "url": "https://wtvbam.com/2026/07/13/mylan-to-sell-up-to-363-million-stake-in-indias-biocon-term-sheet-shows/", "source_name": "WTVB", "published_at": "2026-07-13T21:09:18", "published_display": "13 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 58, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PFE5282055 Bond Risk Profile", "summary": "This page provides a risk profile for the Viatris Inc. (PFE5282055) 4.0% bond maturing on June 22, 2050. It details key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. The pl", "url": "https://www.tradingview.com/symbols/FINRA-PFE5282055/profile-risks/", "source_name": "TradingView", "published_at": "2026-07-13T19:39:19", "published_display": "13 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mylan to sell up to $363 million stake in India's Biocon, term sheet shows", "summary": "Mylan Inc., a part of Viatris, plans to sell up to 92 million shares in Indian drugmaker Biocon Ltd, amounting to approximately $363 million. This secondary sale represents up to 5.64% of Biocon's outstanding shares, with Biocon not receiving any proceeds from the transaction. Th", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/mylan-sell-up-363-million-stake-indias-biocon-term-sheet-shows-2026-07-13/", "source_name": "Reuters", "published_at": "2026-07-13T14:39:10", "published_display": "13 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris unit Mylan plans to sell stake worth up to $363 million in Biocon", "summary": "Mylan, a unit of Viatris, intends to sell up to 92 million shares, representing 5.64% of Biocon's outstanding shares, in an offering potentially worth $363 million (Rs 34.81 billion). This secondary sale will not provide any proceeds to Biocon, and the shares are being offered at", "url": "https://www.business-standard.com/companies/news/viatris-unit-mylan-plans-to-sell-stake-worth-up-to-363-million-in-biocon-126071301168_1.html", "source_name": "Business Standard", "published_at": "2026-07-13T14:34:19", "published_display": "13 Jul 2026 14:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(VTRS) as a Liquidity Pulse for Institutional Tactics", "summary": "This article analyzes Viatris Inc. (NASDAQ: VTRS) through an institutional tactical lens, identifying strong sentiment across all time horizons. AI models have generated distinct trading strategies, including long, breakout, and short setups, with specific entry, target, and stop", "url": "https://news.stocktradersdaily.com/news_release/141/VTRS_as_a_Liquidity_Pulse_for_Institutional_Tactics_071026071402_1783725242.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-10T19:38:55", "published_display": "10 Jul 2026 19:38", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $14", "summary": "BofA Securities has reiterated its Sell rating on Viatris (VTRS.US) and increased its price target to $14. This revision suggests a potential downside from the stock's last closing price of $19.53.", "url": "https://www.moomoo.com/news/post/72780960/bofa-securities-maintains-viatris-vtrsus-with-sell-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-10T12:38:50", "published_display": "10 Jul 2026 12:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive IgA Nephropathy Data And Yen Loan Recast Could Be A Game Changer For Viatris (VTRS)", "summary": "Viatris (VTRS) recently announced positive Phase 3 results for VR-205 (Nefecon) in Japanese adults with IgA nephropathy and refinanced a JPY 40 billion loan. These developments are seen as critical steps in the company's strategy to shift from generics to higher-value specialty t", "url": "https://www.sahmcapital.com/news/content/positive-iga-nephropathy-data-and-yen-loan-recast-could-be-a-game-changer-for-viatris-vtrs-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T00:09:12", "published_display": "10 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Inc. stock falls Thursday, underperforms market", "summary": "Viatris Inc. (VTRS) stock declined by 1.92% on Thursday, closing at $16.34, performing worse than the broader market. This marked the second consecutive day of losses for the stock, despite both the S&P 500 Index and the Dow Jones Industrial Average closing higher.", "url": "https://www.marketwatch.com/data-news/viatris-inc-stock-falls-thursday-underperforms-market-adf526c1-366a73e5eb65", "source_name": "MarketWatch", "published_at": "2026-07-09T21:09:19", "published_display": "09 Jul 2026 21:09", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Viatris (VTRS) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOSU5aNkU5SkpEMDZ1Uk8tWXVzeUJRcmd0aHR0RDhlOE9zbHh4b1Y5dzJjZWd2M3BhaXFDWHZXZlMyVTFtZ241MUR6akk1eEtydHhCdWJPdUs0Nmp6NmZyVUV3QktUNEtrUnRFY2V0cG9fVDhqZEVlWHV3SHhTWllpeUZLc21rS1hTV2JxcXJXVHFlU0cxRjViT0hNdk9ldw?oc=5", "source_name": "Market source", "published_at": "2026-07-09T13:40:05+00:00", "published_display": "09 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Inc. stock falls Wednesday, underperforms market", "summary": "Viatris Inc. (VTRS) stock fell 1.77% on Wednesday, closing at $16.66. This decline occurred during a generally down day for the market, with the S&P 500 Index and Dow Jones Industrial Average also recording losses. The stock\u2019s drop ended a four-day winning streak.", "url": "https://www.marketwatch.com/data-news/viatris-inc-stock-falls-wednesday-underperforms-market-daf21657-e09e77f24f4d?mod=mw_quote_news", "source_name": "MarketWatch", "published_at": "2026-07-08T17:04:00", "published_display": "08 Jul 2026 17:04", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now", "summary": "This article highlights three healthcare stocks\u2014Kenvue (KVUE), Pfizer (PFE), and Viatris (VTRS)\u2014all trading under $30, presenting value opportunities for investors. Kenvue is amid a strategic acquisition by Kimberly-Clark, offering a defined takeout floor. Pfizer boasts a 7% divi", "url": "https://247wallst.com/investing/2026/07/07/3-dirt-cheap-healthcare-shares-under-30-to-buy-right-now/", "source_name": "24/7 Wall St.", "published_at": "2026-07-07T17:38:07", "published_display": "07 Jul 2026 17:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Viatris\u2019 Japan IgA Nephropathy Win and New Loan Shape VTRS Investors\u2019 Next Move?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/viatris-japan-iga-nephropathy-win-090906120.html", "source_name": "Simply Wall St.", "published_at": "2026-07-06T09:09:06+00:00", "published_display": "06 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results", "summary": "Viatris Inc. (VTRS) recently secured a \u00a540 billion senior unsecured term loan to support business operations and refinance an existing loan, with interest rates tied to the TIBO rate plus 1.10% and credit ratings. This financial move follows positive Phase 3 results for its drug ", "url": "https://www.insidermonkey.com/blog/viatris-vtrs-secures-loan-amid-positive-phase-3-results-1795820/", "source_name": "Insider Monkey", "published_at": "2026-07-05T22:57:51", "published_display": "05 Jul 2026 22:57", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS): Most Undervalued NASDAQ Stocks to Buy Right Now", "summary": "Viatris Inc. (NASDAQ: VTRS) is highlighted as one of the most undervalued NASDAQ stocks, following positive top-line results from its Phase 3 clinical trial for VR-205 in Japanese adults with primary immunoglobulin A nephropathy (IgAN). The treatment demonstrated a significant re", "url": "https://www.insidermonkey.com/blog/viatris-vtrs-most-undervalued-nasdaq-stocks-to-buy-right-now-1795978/", "source_name": "Insider Monkey", "published_at": "2026-07-05T13:08:57", "published_display": "05 Jul 2026 13:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTRS Stock Price and Chart \u2014 NASDAQ:VTRS", "summary": "This page provides a detailed overview of Viatris Inc. (VTRS) stock, including its current price, historical performance, key financial metrics, upcoming earnings reports, and analyst ratings. It also offers insights into its sector, industry, and corporate information, alongside", "url": "https://www.tradingview.com/symbols/NASDAQ-VTRS/", "source_name": "TradingView", "published_at": "2026-07-05T07:39:12", "published_display": "05 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Refinances $247.7 Million Term Loan", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/viatris-refinances-247-7-million-105651551.html", "source_name": "MT Newswires", "published_at": "2026-07-02T10:56:51+00:00", "published_display": "02 Jul 2026 10:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWldfWFV6NXFPUmxoWWRPZDU2TnRBX18tdHdXN1AwQk95Mmo1al9LTzA0TnVjd3U3ODBmcmdmdngxNTA2S05ma3lKN2hvN2RqOW9DclAyUWlUWmcyakxKVjVyNl9Jc0FxZk1wcEc5SHRmS3VtQVN2MjJTcjluMHdJQlk5b1dRQXRxTFBUbFZhZTVibjhqbmRCZllGQTctWFk?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T11:53:51+00:00", "published_display": "01 Jul 2026 11:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris sets Aug. 6 call for second-quarter 2026 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQV0FnblV2NlNmelNfcVJnTHIzZzRnUWFUSVhGT2doMlFhRHhkZWFab3huN0FwdWtjZ0N3VGM1RXVuSF85VEM3cWpodGZBSFhwUVZIb1dFR09CLTVkRzJBU3FyS2xYWEtlbWloWklGdFZJeko2c3VnbVRmZWlXTXZKRm45bUFtV1FXa01SMTNkU0FNUnNqTS1OWHAxMldKSmE3NGdZcTVxeFNGTmNCbjkyOXdnd2c2Tmg1cFJTcXZXSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQc3RxX0MwQ2Y0bU9VaHJjYVJJNkxpMm15M09EOHNaeXl2QWZPNTZmSDgxamJHdFE2cnoxLUU3OUNxOGcxSVQ1LUtfa0xUR2V1dkdPSEttT3ZIc2NpdkQ0VnNjM0VWYk9fenJlX1ljUjVpRklNQjQxdS15M1hjX3FVSEZsSWhYcHJaTDcwZVNuZjRpWU9OanhZZDg0andOR1ljQU1HVnowMEY?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris kidney drug VR-205 cut protein in urine 33.75% in Japan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMzBMQm1PTjZHQjhGMHhydGc3V0w4Y1M2M3B3UDB0NDNfc3pram0zZVRkdFFMTUx6aG1MYVNNNV9KMEpXXzdWWXdHMVJjSUNxU0lkN2UtUGhtUkJiNEtRaWFQNmtOaDI2b1M3VEZfZ0t5NjItYjY0VWxxTVN3THh1SlpUcl9VT2RiMUgyRTVJbGc2MG05M25xM3lNTFV3d2l2ZVBpbW5FbHhrc3RhaFhNWjk3MHRrZFNLTlhXNXk0NUk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPNlhGRkkyWWJ6dFo2akxUVVJuNWZVMTIyZTlyODdxYmxfRkZOWGdJc0pyMDVNRi02cy1jcERiSm9lNzgtSE92NG1ITEsyS2JKYnlISFhUQm5SbG1sX212UUI5MllfbEE2d0VHVzBRSDBpcVdzWVRsUFdaT2dtRGNJUEx1WDBodTdtS0ktamlCbGxPUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Investors Undervaluing Viatris (VTRS) Right Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPdm1EY1ItZDB2NHNVVVloYk1DSGNrdFNkT3pDX0xtRlIzWFRDUjVldDhhcGhIZndoT2dQbXh4MHRaNzE1RkdIODJkQXpsVVI2ZlZVVVN6NDV2bEYwdHFBSXgzQkQxQ1ItNU1mZTJjd0RndVZlc00zZXZtN1djNDE0Z2F4WDBLUXNzeXhpUHR2QmU2b2dwRlNZZzZYUW5qNWF5UjlCU2MxWQ?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOLUdCcnhvb1ItdGFnMGViU0xJS2RTNHhMbWZXY0pQZzRzWEplTGhKSkZ2QVV1Nm5KdldjWi1ON3hSMVBSQTBST0ZIaWNlc0hTM2NPSUtBcW9UdWdZUkEtLWp3RXJ6dUFvT1VxX3ZIT1Y2clhHUlFiVlFqSzcwblQ2N2Z4Q25NWGowQ251TnU0a1VpcmNna0laaE9CYnUxdEtiTkdNTHVsRkRDVWc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (NASDAQ: VTRS) issues \u20ac650M 4.25% notes to help refinance 2026 debt", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQeFV0OW5xcFlxQWdKWmFlck5JbG5TMXdoSFFyajA0bHhEX082VFQ1c0g3VG5ESGdKWEgwUkJMck1vby1OeDhUaWJraVhQTkRJUEZtYkdveDF2UWd5N21HVk16Qm9jSC1YVS1CMHdGVkZ6MkUzY1QwUDRILS1yMmNBY2w2dUZ2SWFaX0tLYlNtaVB0NGJEdzd3bEJzR1owOFlSd3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSF8tX0FQYm9VUzdLazA1bjhsMWNraV8wLVJGNnNxYk1Xemc4WUxiZGF6LXlRMjNJX0RpaHFreC1IalNYODhpN01PdXhib3NTeU9GY1l3Um5OLXVaZ18taFFFV1RoaFptOVZ5Vm52LTdCSUtIY2ljX2FNanR5TmNRR3BrUTRuOHJIUG5lUlpyN3E1YW5taV94Q2VUZGE3Y3ZrQjVn?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS): Buy, Sell, or Hold Post Q1 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQOHlLMGRzNDRfZlpiS0pBcTRsek1zOVVuNVN1WHo5NmNqU29OcS16YXZpZXpZSTZ6cWhWYm5EM1dOUTVqcFRZaXpiQVdwS2lCZmNTVXRmNlBkMlBVeW4tekxzZlNKLW91NDFMaC1XN2hVWEdDRG1VQ1FmcjEzRjl6SkF6anhxdVdkdGwxYUk5bmdCZlhzaXc?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQUmJ1U0VSY1hqRUt4MnpWUkpMY29tbnRYMUxZdmkxVTM0M1JOd1FaWENYaVJWbzBWU3J5N0x4UV9YM0dDeTdRWW1KVXppNTRUUkVzdVY4RlVqa1E5OEg4cVVoY2p3Vms5bWNQQ3U3NzV4Szdmb0FqX21HanVOSTU2OTBYOGswcWkzc0NGbW1mUVBONHlYNlQ1c1RPQVBOQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New non-opioid pain drug from Viatris faces FDA decision on Dec. 27, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOVnZnbDh4UTZPMWpXZ2lGU3Z0OGt5SEhJX0Ytcl9oczg2Y2EwVDZodmprV2t4NUo1Rlk5UmhyYmFaS3E0bzhJQmktYTBKNlppTmgwSmYwWXZ4YXBacXhMVGNpUDRuY2ZFY3hFR2tuUGFSUjR0WkVqNFpwVThSb2JJbnh6OUF4cTF5MElOT04wQ0pUZGRCWC1IVGhnOXliekl4YThXV2FFaFY3ejd5ZjhrOVg1RTVDdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After Kicking Off 2026 Solidly, Viatris Looks to New Launches and Cost Savings for Long-term Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQdTByUUg1VmM4YjlDUWZqMzVLa2xUZjFyMzU5clVnVndMdEljSmxjSVAyV1hrVThlVm9XLXFDLUx3Umk1dXF2UUNaMmhaTE02UVhuR3dBVlFXbVEtb2dPMFFNaTl0SmdWMGEzazVOOEdSejVIcWRUNWhuenNZR0RRbjFtQ2FqdTBfTkREQU5QZjBUMXRrbTZydWFXa3RCbEtxTlNXc2hveTgtenAxOUZFcldDOWRzTUM0VWsxODFqbmRpcmFxSl9VRFcwaHd1TWJ3Ni1wRklKMnFONWlKSzNxQmtGTkE?oc=5", "source_name": "Morningstar", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris\u2019s (NASDAQ:VTRS) Q1 CY2026: Beats On Revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxON3RGZGo0dFVuQXpkNWZPUFAtZDJSdEowTzRtcDJjbE4yQ0xkXzhEZHNKd3hZaHY2eW82dnhPc0hEckhBZVo0amtSd3NtZmtvb2RLY3pROTJ6SS1EQkxVM2Fycy1RR0NQNWtaUDMyZDQzWWFxOUdoRkM3YXlQejYzRmpFME9uSHZ3OV9EWVppV3BvUHpCSDRiS0JB?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPdzFiOHNsX2xncWlWdnl2c1dVbWppUXZILVNuby1UMTlfenJFeTd0OEwyWEpoWmg2TFFoMDZLOGwzY3RWa2tCUmN3N0pPNmswMG1udF9NVnlOREZGVVZzb2dfbmZpY05iZWIzWDRxd2NQb3hoRGJ0M2F1V25HaGozWV9xb20zUThGTEthRkZJWTE3MXBM?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris (VTRS) Heavy FY 2025 Losses Keep Bullish Turnaround Narratives Under Pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxQb01LV1ZYUThwaUE2TnVYS0J0NHlicEY3cHZYZWNWMzBCa0xrTHY4ZHNuRTZ2RFljWW9EcVgwM3VEUFdMZGdNT3g0ZlI0Nm90clc5N0lZLTBDcWloTHJmQk80RUNtMnF6UG85TWU1eXYtNXJZSEtGOHhyWXpWX1Rzc09mVTVDbXVqdlU1SXBfTTA5c0wtTTFBQVEwQXUxSUlXdHgzRk0zQUpHYWRPeHhXQW5NZ3ZabUVHTUp4LVo5UFowcTF2OHdlZDhhNHlxMXcwTkMzYWNIOULSAd4BQVVfeXFMUHlHckJwZjBOcVdNSzVPclpHaFg0VTl1Z0VwandXLXk0X2lJNV80MWUxNmhzRVhJaEdXY2xIcDBaeWZwZ2hEbUptdWUwS1Y3M2pmcHRleEowOENScS0tOTZNOU80djdEXzNSRl92OEduaFRzY2s2NmttSGd1azBzUlNfdi03YzdXQW5iS3NBc1dFT3lzaUtCaFdPRTJmNEtEZmFUQ0RpNDVaaXJlRWZsV0FyZkR1ZDFTd3R2bE5tZE9FcUF5RXFUVjdWeDROdnhxV2NoZHdtWW40UEQtUV9n?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Reports First-Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOQzN4MmVad1pXU2RZR3RDaDE5YW94SkVJMzZadF9qRDltOW1EX0Y1aDhSYnp6ZGxiNVNLamo1RFBxUk5SUmdTa0ZpUEE3Vno4aGo0TWlEdEs3blAyNllMRF80aEwxRkFQcXJZMzR2Zkx5N2gyWE1GVWVkd1dROEZUUEIzWjBJNzhVMDdyTmdSS2hwN3VFRThXTzlvajAzSjViTlFBMFIwdHlRSEJf?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Viatris (VTRS) Valuation After Its Recent Share Price Rebound", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOb0VXellib3lsM0JjNnBjTlQ5M3g3WkJMcGl6UE5VSU5VRXFkeWd6SW5OcWJtYUNXZFlpWFFYZEtYRmgtODZqMURaVEhadnh1Y2taRU1pa0liNkZVc0xSa3laVngzUXN5VXNjNEJDTGx1WWpMSUU0TEVxUzREaDVGaW41SVdFc0k5ZVQ2ZXZlOU53aGxsc3ctR0FkdzltQ1dOb2RqNFM4MA?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are Wall Street Analysts Bullish on Viatris Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQd0RPWEluUFZjTm5OZHJFUHZ2cUxNd2V0aENPNzBZNjdrb19ZZ1J5Y0QweklrY09mV1hGSWdyQXVwYkw1Y25kQW5ua3dIZkNTX0xSbEdJSWVkbmJCWk1hWjhneWwzLXZ2dW9TbTNrc2hwNmNuN3UzMFVmY1RmcGZwSS1rbWdKOEFWR0ctTUVCVjdkV3ZZRVNmY1BJTUI2ODFQT1Bj?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Davis Selected Advisers (NASDAQ: VTRS) reports 78.21M shares, 6.8% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOcHk0bjJqRWpBMGxtaktNZ0Nfa1hQMnNzQ0lOU0hLMm9iRXNibkpTRmhuVVlPbUdCcWdsNTJkb3JiQkpMMWhjcldOTzVWbGxjSGVRU2c0Y2tNS2tZVXlPbjlnRFBEMkxZTjVmMTVyeXZuYTA3bXA5RUhscGtMdmcya2Y1dXZQUkRaUlNzOXJBakp1SjFzM3lXOC1nR1drRllVbmJxNDZ3bk9qSFdqeTNpMlVkVlBMM0xabW5oXzYxSC1Xd2Rm?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Viatris (VTRS) After Its Strong One Year Share Price Run", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPZnBKVlhlM2VpbVdJRzV2dmxTQ3Vna0pRMGdOWXduRk1BdnpoYkVvZF9hTUVFdmc2Ym55N2k3dXpTcUhGNVNybXZGa3A3b2NIdHdyMERlSEp2TmhkZlJ0S2FrRmtMUVNhcXZENk9EM0g4ZmhnUnpBTmJpWmd4cWRIampUREdmc3lkUjBiOG81UVZTUGQ5azZmVl9TYTJLZw?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Contraceptive Patch Data Puts Women\u2019s Health Growth Story In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNbHAyMW02dmM1OE1pd2ZyMUd4UmZ2Y3JoSUdoYTBQbGU4dGZQUlgyU0dTQVUyQndlMFZuTjBJSWxNNGNQTDR0cmVhVWU0aVJNMHVmVG9ISFlxTnJHcXBCRzJmaDVkUG54T0VKc1VfVjB6MjVXdkMtYWdHeHliSDF0T2ZLZ0xlai1fNmhOYlBYSjlhRVJLWXpfQWxETjJ2NXZaMW9iVVNYS0Z3eWdYYnhwNmVWbnl0aHFvZU42VU9PN0FOQlQ3d0R6UGhDRnJJT3dGSXVaZjg1WHPSAd4BQVVfeXFMT082X0xwUU1aU0RaVGFOWG5BMDdQLUZjeUs1Z1M4b0t1N3M2LWtDaHc1eW14elE1ZUk4Z2dNMy03LXgxYi1CTDNhZEREa2J4NmR6TmY0Vkd3VktadkVldXl6OFJDWW1TWHBkWGpnQ284YzUzdmVzUFU3TWMzVUxtY0ZXSkNlTXZiSHVDUU4zcWtlWlBBQklQUEN1UVQ2TGlDWS04REF4WUx3d21rTlRzQVIzZjRmMzMxdl8xd3kyc0pNOXhWcFJlTDFJQm1TQnpsVjMzQkhCdEQzY0dDQ1Zn?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Viatris (VTRS) One of the Best Medical Stocks to Buy Under $30?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQQjNCQnZwTkZKR1lTNEdhRlNQVTNTaVJIR2xfVTJqYmZfYnNQaFcwUHVFNTFMR2ZaVS1sSV9idmxWTll0UGd3U1ZVNzZha1VXZlNrWDVzSFJYV1lsU01ZcWVoWmRYdFFqbUxBM0N4QXlIWThzZXo4b0h1OVhuNXBmY3h3VUhaTnZWS3Q0emE0VVVxcC1pOEtNeUlB?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard discloses 7.36% stake in Viatris (NASDAQ: VTRS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNbmZvVFBTcU5wOTVSbTNqQzZLT0d3V0VGTUNwMlRRY1plODF3UV93Y2I1b2taRm1xSEVPY2VxVWJoSS1odHVJNDRhUzVkN2Itb3ZYWUI3TUotVXBTWlRRUkZCOEgtZ0tzb0htdzVCanZwaENMMlRoSm1yZVYtVXVhOGlfeXNkUWJRTDZRY2hRQWpDRktzOVVBRmw4dkhEdDJOeXlpU3FYd2c5cDFzMy15MnZKWEhpVm9sbEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris, Teva kick off separate recalls over dissolution, raw material issues", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSEY1Y0VZNWh6OU0wU2Jmc2tqRXdQSUlUeWlnZFBMcldhTjVabUtrbFlTZmlqand4alg1NjVZZmxnSzgtXy1hY2xDeXlkMjQ3SWtmZmUtOXdCbFR4N0p0Vm9nTGRBQlFTOVpXZU5EdXJ6b25HcVZVQ3BDY0U0RU15TGRJcV9WWE9feHpjc3VRNFNlOFdRQngtNGZSOWVibndtVENUeEl4ZVpRWkhjLVFjWVFlOWZLZUVfMFFnSGFndFE1WkU?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPcHdSNEhpWnZwX3ptTVFTTmF1YWZSSDlkLS1iSkRIU3EyZFpfNzhGNjJ4VDVWV01KbW05UW9CbTIta3FWYzhqV0c3S2p5Qlpzak9icy1jZlBsNkM2d3lsTG93R0t1bzAzZWRodFdqd1NjblNBUnlMc1VFN183Rks4b09mMDEtNHFXdzlZVDlCV1dNckd2X2NjX2JaT0tUY202emZXRG5ubEtiR0dkaVR0aVY3NGF0WE1ORzloOVI1cEpjdXN6UHhsY1QtUE9xcUJLMjFhVkIwTQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Are Analysts Saying About Viatris Inc (VTRS) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxNbUx4cTRRd2xNZVd2S0lTci1KUXNNLUUtTzY0WkNtWWZfZkt4cnhpUlhJUTRvLUJaeEhjVjBEWHJJWGZIZDJYb3JBRE5Dendfb29HaHhkZVQ5V1FwakJPQTZSekVoeC1zOWxweTVFZjlqWGpCY2VOdkNIU1ZySFZlWVBjcXI?oc=5", "source_name": "Market source", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNMkxMWTBBTHZmUFktRzN0LVdQbDBzNWFGV0ZkSGZBZHp0MGViT1g1S3V0d0EzSVM2ejh0VjdiQ05oUFA4MGx0MDg0VnJJTU1rWXVVeVVXQ2wzZVNsZEdsVFR6VUd3WjVjNUJBRTFFMjJvOWY1a0V3S2xIamJGLTNHSExKV1pOX081SmlnZGRXX2QzWU5XOGZBS0tYbHgzTjBwQ1AxOUY0MVZBR3pRVHBjdGNFYmZkRHdWalEwcFBMc2E?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where is Viatris Inc. (VTRS) Headed According to the Street?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNTTdOeW1TZEhTU3E3RHE1UWpwUUVpdUVMSU1YRG5DYkF3SkN0Zm9RR2R5MG5xOEV1Tm1tMW1pVV9rZU1hd0xpbkg1Z3ZQeTlNMU1DRE5RalFzY0U0RXZ2LXMySWluYU9SRXhrSE01dkVVVjdRU0V6NUtxMDc2MTFxZA?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Viatris (VTRS) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1jeVp4Z1hSeVFhdU8xYlRUeEVabWtmV2dGbVVsU1hySzlOZVdiaXVrZTZpXzdFcm1odGhjYWhtTzhuZ0hHTWNvNm1SbXdNaFFMaEs4YUI4ME44UkxueklfU3c0dnQ3SUZ0dk9iRE96M3laNnBjNXZFMzVmdXNQYW8?oc=5", "source_name": "Market source", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNQnZQR3NNUTBmSWs4QllVaTBiYS1POGM4RWpHc2tZV3VLUFNiWG1hT2VncE85cy12MmpMcWQ1cG84bjBJN3Vicjg3aHVZQy1XcHloQ3ZoUUNVUmlPbUlsU2pVZURXZ1VMcTVGZlk0TkJiNm9fWV9WUzhnVGpNMklrbFc5TzZsZlgzNXlZNmhkaW5WVWxvQmw2bDBka0tUUjRTTVBCUHVmenhhQ3BjSFB5c0E2WlJLcGJKUnc?oc=5", "source_name": "Viatris Newsroom", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 92, "total_relevant": 53, "sentiment_summary": {"positive": 20, "negative": 5, "neutral": 28, "score": 54, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.7, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 4.0, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 3.45, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.9, "count": 1}], "positive_events": 20, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 16.27, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": -1.3, "twelve_week_move": 11.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.368986, "market_dynamics_buy_signal": false, "relative_strength": 12.269568, "fair_value_gap": 51.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.4065, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, -1.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 15}, {"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 4}, {"label": "MarketWatch", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "PR Newswire", "count": 3}, {"label": "Morningstar", "count": 2}, {"label": "Insider Monkey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "9", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.6% over one week, -1.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Viatris Inc. stock rises Wednesday, outperforms market"}], "updated_at": "2026-07-16T12:41:17.547848+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}